On 6-7 June the kick off meeting of MTBVAC in Newborns took place in Cape Town, South Africa. This project contains a Phase 2a dose-defining safety and immunogenicity study is being carried out. The project includes also capacity building to support vaccine efficacy trials in Tuberculosis-endemic regions of Sub-Saharan Africa. The project is part of the EDCTP2 programme supported by the European Union.
Project partners from South Africa (Satvi, UCT), Senegal (CRB-EPLS), Madagascar (IPM), Spain (Biofabri and Unizar) and the Netherlands (TBVI) attended the meeting. Also a representative of EDCTP, Tom Nyirenda, joined the kick off of this project. Furthermore, the Steering Committee held their first face-to-face meeting.
Work package leaders and members had the opportunity to be introduced to each other and to discuss about the study approach. The South African partner Satvi hosted also a visit to their field site. The meeting turned out to be a wonderful and promising start of the project.
